Why the joint environment decides candidacy

The question patients often ask first is not 'what is ChondroFiller?' but 'why am I not a candidate?' The answer lies in how the treatment works at a biological level.

ChondroFiller is an acellular collagen scaffold — it carries no repair cells of its own. Delivered as a liquid that sets within the joint space, it functions as a chemotactic matrix, attracting the body's own progenitor cells to migrate into the scaffold and begin producing new cartilage-like tissue. The injection is the structure; the body must supply what actually builds within it.

This dependency has a direct clinical consequence: the joint's local biological environment must be capable of supporting that repair. Where that environment is disrupted — by advanced degeneration, active inflammation, or systemic disease — published clinical data indicate that the scaffold cannot fulfil its role, regardless of the size or location of the cartilage defect.

That is why exclusions from ChondroFiller candidacy are environment-based rather than defect-size-based or age-based — a distinction that surprises many patients. The sections below group those environmental barriers into four practical categories.

Absolute contraindications that close the door on treatment

Several conditions represent firm safety barriers — situations where treatment should not proceed regardless of cartilage defect profile or patient age.

Known hypersensitivity to Type I collagen or murine-derived proteins is an absolute contraindication. The scaffold is composed of murine-derived Type I collagen, and the risk of a serious allergic reaction in a sensitised individual is unacceptable. Any history of reaction to collagen-based materials should be declared and investigated before any assessment proceeds.

Active infection — whether localised to the joint or systemic — also closes the treatment pathway. Introducing a Class III biologic device into an infected environment carries a meaningful risk of seeding or worsening that infection; the joint must be demonstrably infection-free before the injection is considered.

Pregnancy and breastfeeding are further exclusions. Published safety data for injectable biologic scaffolds in these populations are absent, and clinical caution applies in line with standard practice for novel implantable devices.

Beyond these three, the manufacturer's clinical evaluation identifies periarticular tumours as a non-negotiable contraindication. Current clinical guidance also excludes active clotting or haematological disorders — which can impair the body's healing response to the collagen scaffold — and arthrofibrosis, where fibrotic scarring so severely restricts the joint that it is unlikely to support scaffold integration. These represent fixed boundaries of the treatment's safety profile rather than factors to be weighed case by case.

Advanced osteoarthritis and inflammatory joint disease

Among all the reasons a patient may not be suitable for a collagen scaffold injection, advanced or generalised osteoarthritis is the one encountered most often in clinical practice. The distinction that matters here is between focal cartilage damage — a discrete area of lost or damaged cartilage within an otherwise serviceable joint — and widespread, multi-compartmental degeneration that has affected the joint as a whole. ChondroFiller is designed for the former; the latter removes the conditions the scaffold depends on.

In advanced osteoarthritis, two problems compound each other. First, there is little structurally intact surrounding tissue to anchor and support the gel after injection. Second, the biological environment within a heavily degenerated joint is predominantly catabolic — tissue-degrading signals outweigh tissue-building ones, suppressing the cell migration and differentiation the scaffold relies upon. For the hip specifically, Tönnis grade 2 or 3 represents a recognised clinical cutoff. A published cohort study of 26 patients with follow-up extending to five years (Mazek et al., 2021) found that patients with pre-existing Tönnis 2–3 osteoarthritis achieved poor outcomes following collagen scaffold treatment — direct clinical evidence rather than theoretical reasoning. A specific Kellgren-Lawrence threshold for knee patients has not yet been defined in a controlled trial, so knee candidacy is assessed on clinical and imaging grounds without a single validated grade cutoff.

Inflammatory joint disease — including rheumatoid arthritis, psoriatic arthritis, and metabolic arthropathies such as gout — constitutes a parallel exclusion. Here the mechanism is immunological: active, immune-mediated synovitis alters the joint environment in ways that interfere with scaffold integration at a cellular level, undermining the repair process regardless of defect characteristics.

Patients who fall into either category are not necessarily without options; they may be better served by a different treatment pathway, and an assessment can help clarify which direction is most appropriate.

Structural requirements: defect containment and joint alignment

Two mechanical prerequisites sit alongside the biological ones: the defect must be physically contained, and the joint must be correctly aligned.

Defect containment refers to the presence of healthy cartilage forming an intact border around the damaged area. After the collagen gel is injected, it settles within that space and must remain held in position while the scaffold integrates with the surrounding tissue. An uncontained lesion — one where the bordering cartilage has also broken down, leaving an open or irregular margin — provides no stable housing for the gel. Without those intact edges acting as a natural wall, the scaffold cannot remain anchored at the repair site.

Joint alignment and stability matter for the same spatial reason, but across the whole joint rather than the defect border. Clinical guidance typically cites uncorrected malalignment of approximately five degrees or more as the threshold at which leg-axis deviation places excessive, asymmetric load on the repair site — enough to disrupt integration before it can consolidate. Unresolved ligament instability creates a comparable problem: abnormal movement patterns repeatedly disturb the scaffold before it can become established.

Importantly, neither of these is necessarily a permanent barrier. A patient currently excluded because of malalignment may become a candidate once the alignment has been corrected through appropriate treatment beforehand. That prior treatment — whether surgical or otherwise — is a separate clinical step; the collagen scaffold injection follows as a distinct outpatient procedure once the mechanical environment is stable.

When a different cartilage pathway fits better

The injection's design strength is also, in one specific scenario, its relative limitation.

ChondroFiller works as a whole-surface coating: distributed across the joint rather than targeted to a single point. That broad-coverage approach is the clinical advantage when damage is diffuse, multi-area, or spread across compartments — the treatment addresses the whole cartilage environment without needing to localise to one spot. For most patients who reach assessment, this is precisely what is needed.

There is one profile where that strength inverts: a single, contained focal defect within an otherwise healthy joint — intact surrounding cartilage, healthy bone, good biological regenerative capacity, no generalised degeneration. Here, broad-coverage injection is less advantageous than a procedure that can deliver scaffold support precisely to the one affected area.

The pathway described for this scenario is Liquid Cartilage™ — a distinct surgical procedure involving targeted scaffold delivery directly to the defect site, not an outpatient injection. Where the clinical picture shows a single focal lesion in an otherwise pristine joint, published guidance suggests this surgically placed approach may offer a more concentrated regenerative outcome than whole-surface coverage can achieve.

Critically, this is a pathway-fit question rather than a safety concern. The patient remains a cartilage-repair candidate; the issue is which route matches their damage pattern. A clinical assessment determines that distinction — including whether the focal-only profile genuinely applies, or whether wider joint changes mean the injection remains the better-fitting choice.

What does not disqualify you — clearing up size and age assumptions

A significant number of patients who would otherwise qualify for collagen scaffold injection never request an assessment — because they assume their defect is too large, or that their age alone rules them out. Neither assumption is supported by the clinical evidence.

Published clinical data report use of ChondroFiller in lesions of up to approximately 6 cm² in carefully selected patients — considerably larger than most people expect the upper boundary to be. There is equally no upper age threshold in the candidacy criteria. The reason both assumptions fall away connects directly to how the scaffold works: as an acellular injectable matrix, it does not depend on the patient's own biological regenerative capacity in the way a surgical repair procedure does. It provides the structural environment; the surrounding joint supplies the cells. What clinicians are actually evaluating is whether that surrounding environment — the degree of degeneration, the presence or absence of inflammation, the mechanical stability of the joint — is capable of supporting repair. Those are the variables that determine candidacy.

The practical consequence is that patients can reasonably self-exclude on entirely the wrong grounds, while the factors that genuinely matter go unexamined. A structured clinical assessment — reviewing imaging, joint environment, and medical history — is the only reliable way to establish suitability. The assessment form on this page is the appropriate starting point for that process.